Abstract

BackgroundWe previously reported that IL-6 and transglutaminase 2 (TG2) were expressed in more aggressive basal-like breast cancer cells, and TG2 and IL-6 expression gave these cells stem-cell-like phenotypes, increased invasive ability, and increased metastatic potential. In the present study, the underlying mechanism by which IL-6 production is induced in luminal-type breast cancer cells was evaluated, and TG2 overexpression, IL-1β stimulation, and IL-6 expression were found to give cancerous cells a hormone-independent phenotype.MethodsLuminal-type breast cancer cells (MCF7 cells) were stably transfected with TG2. To evaluate the requirement for IL-6 neogenesis, MCF7 cells were stimulated with various cytokines. To evaluate tumorigenesis, cancer cells were grown in a three-dimensional culture system and grafted into the mammary fat pads of NOD/scid/IL-2Rγ−/− mice.ResultsIL-1β induced IL-6 production in TG2-expressing MCF7 cells through an NF-kB-, PI3K-, and JNK-dependent mechanism. IL-1β increased stem-cell-like phenotypes, invasiveness, survival in a three-dimensional culture model, and estrogen-independent tumor growth of TG2-expressing MCF7 cells, which was attenuated by either anti-IL-6 or anti-IL-1β antibody treatment.ConclusionWithin the inflammatory tumor microenvironment, IL-1β increases luminal-type breast cancer cell aggressiveness by stimulating IL-6 production through a TG2-dependent mechanism.Electronic supplementary materialThe online version of this article (doi:10.1186/s12885-016-2746-7) contains supplementary material, which is available to authorized users.

Highlights

  • We previously reported that IL-6 and transglutaminase 2 (TG2) were expressed in more aggressive basal-like breast cancer cells, and TG2 and IL-6 expression gave these cells stem-cell-like phenotypes, increased invasive ability, and increased metastatic potential

  • TG2 overexpression in breast cancer cells results in epithelial-mesenchymal transition (EMT) and stem-cell-like phenotypes To define the signaling pathways involved in TG2dependent IL-6 expression in breast cancer cells further, TG2 was overexpressed in otherwise TG2- and IL-6negative luminal-type breast cancer cells (MCF7)

  • Since increased aggressiveness conferred by TG2 expression in breast cancer cells correlates with EMT and stem-cell-like phenotypes, these characteristics were evaluated in TG2 overexpressing cells

Read more

Summary

Introduction

We previously reported that IL-6 and transglutaminase 2 (TG2) were expressed in more aggressive basal-like breast cancer cells, and TG2 and IL-6 expression gave these cells stem-cell-like phenotypes, increased invasive ability, and increased metastatic potential. The overall disease-free-survival of breast cancer patients has increased tremendously, the therapeutic options for recurrent and metastasized breast cancer are limited [4, 5]. A detailed understanding of the molecular mechanisms underlying breast cancer aggressiveness is important to develop novel therapeutics for recurrent and metastatic breast cancers. Among several explanations for tumor recurrence, cancer stem cells (CSCs) are the most fascinating and relevant. Due to their stem-cell characteristics, CSCs have tumorinitiating capabilities and are drug- and radiationresistant [3], and are believed to persist as distinct populations in tumors and be associated with drug resistance, tumor recurrence, and metastasis [3, 8]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call